BONESUPPORT Gains U.S. Trauma Momentum with Positive CERAMENT G Pilot Study

The latest update is out from BONESUPPORT HOLDING AB ( (SE:BONEX) ).

BONESUPPORT has announced the first U.S. clinical pilot study publication on the use of its antibiotic-eluting bone graft substitute CERAMENT G in trauma cases, conducted at HCA Florida Kendall Hospital. The study, published in OTA International, provides practical, technique-focused guidance for surgeons treating fracture-related infections and osteomyelitis.

Patients were followed for an average of 14.4 months, with the authors reporting no recurrence of infection, no major complications or amputations, and radiographic bone union across all cases. Management says the results, although from a single Level-1 trauma center and pilot in scale, support the effectiveness of CERAMENT G in intramedullary use and strengthen BONESUPPORT’s position and momentum in the U.S. trauma market by aligning with common American surgical practice.

The most recent analyst rating on (SE:BONEX) stock is a Buy with a SEK220.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.

More about BONESUPPORT HOLDING AB

BONESUPPORT Holding AB is a Sweden-based orthobiologics company that develops and commercializes innovative injectable bio-ceramic bone graft substitutes under the CERAMENT brand. Its products remodel into the patient’s own bone and can elute drugs, targeting complex bone injuries and infections in markets such as trauma care, with net sales of SEK 1,175 million in 2025.

Average Trading Volume: 288,023

Technical Sentiment Signal: Hold

Current Market Cap: SEK12.34B

For a thorough assessment of BONEX stock, go to TipRanks’ Stock Analysis page.